Precision Medicine in Solid Tumors

• Awduron Eraill: Dey, Nandini (Golygydd), De, Pradip (Golygydd)
• Fformat: Electronig Pennod Llyfr
• Iaith: Saesneg
• Cyhoeddwyd: Basel 2022
• Pynciau: Medicine; Oncology; pediatric tumors; tumor mutational burden; TMB; whole-exome sequencing; gene panel sequencing; immune checkpoint inhibitors; glioblastoma prognosis; overall survival; extent of resection; random forest; Decision tree; personalized precision oncology; circulating free DNA; liquid biopsy; epidermal growth factor receptor; tyrosine kinase inhibitor; osimertinib; comprehensive genomic profiling; molecular genotyping; intratumor heterogeneity; multiple biopsies; tumor evolution; clonality classification; strategic therapeutic intervention; thymoma; driver mutation; sequencing; molecular barcoding; EGFR mutation; EGFR-TKI; cfDNA; NGS; digital enrichment; next-generation sequencing; solid cancer; universal health-care system; precision medicine; presumed germline findings; clinical guideline; non-small cell lung cancer; outcome; adjuvant chemotherapy; anaplastic lymphoma receptor tyrosine kinase; HNSCC; ctDNA; tDNA; DDR genes; PARP inhibitors; new drug development; next-generation sequencing (NGS); open data; regulatory reform; tumor profiling test; triple-negative breast cancer (TNBC); breast cancer; targeted therapy; TNBC subtypes; immunotherapy; cancer; screening; smoking; electronic records; PD-L1; cancer-associated fibroblasts; resistance; chemotherapy; CTC; immunocytochemistry; parallel double-detection; laboratory-friendly; n/a
• Mynediad Ar-lein: DOAB: download the publication; DOAB: description of the publication

In the era of precision medicine, the use of molecularly targeted therapies in selected patients has led to a paradigm change in cancer treatment. Multiple studies have demonstrated the benefits of therapies that are chosen based on the molecular profile of the tumor and also from the liquid biopsy....